# Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

> **NCT06341712** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 10 (actual)

## Conditions studied

- Osteosarcoma
- Osteosarcoma in Children
- Osteosarcoma in Adolescents and Young Adults

## Interventions

- **DRUG:** Cabozantinib
- **OTHER:** Best Supportive Care (BSC)
- **OTHER:** Best Supportive Care (BSC)

## Key facts

- **NCT ID:** NCT06341712
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-11-22
- **Primary completion:** 2026-02-27
- **Final completion:** 2026-02-27
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06341712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06341712, "Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06341712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*